Literature DB >> 20420825

CD14+ monocytes promote the immunosuppressive effect of human umbilical cord matrix stem cells.

Ding Wang1, Ke Chen, Wei Ting Du, Zhi-Bo Han, He Ren, Ying Chi, Shao Guang Yang, Francis Bayard, Delin Zhu, Zhong Chao Han.   

Abstract

Here, the effect of CD14(+) monocytes on human umbilical cord matrix stem cell (hUC-MSC)-mediated immunosuppression was studied in vitro. hUC-MSCs exerted a potent inhibitory effect on the proliferation and interferon-gamma (IFN-gamma) secretion capacities of CD4(+) and CD8(+) T cells in response to anti-CD3/CD28 stimulation. Transwell co-culture system revealed that the suppressive effect was primarily mediated by soluble factors. Addition of prostaglandin synthesis inhibitors (indomethacin or NS-398) almost completely abrogated the immunosuppression activity of hUC-MSCs, identifying prostaglandin E(2) (PGE(2)) as an important soluble mediator. CD14(+) monocytes were found to be able to enhance significantly the immunosuppressive effect of hUC-MSCs in a dose-dependent fashion. Moreover, the inflammatory cytokine IL-1beta, either exogenously added or produced by CD14(+) monocytes in culture, could trigger expression of high levels of PGE(2) by hUC-MSCs, whereas inclusion of the IL-1 receptor antagonist (IL-1RA) in the culture down-regulated not only PGE(2) expression, but also reversed the promotional effect of CD14(+) monocytes and partially restored CD4(+) and CD8(+) T cell proliferation and IFN-gamma secretion. Our data demonstrate an important role of monocytes in the hUC-MSC-induced immunomodulation, which may have important implications in future efforts to explore the clinical potentials of hUC-MSCs. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20420825     DOI: 10.1016/j.yexcr.2010.04.018

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  23 in total

Review 1.  Stem cell-based therapies in ischemic heart diseases: a focus on aspects of microcirculation and inflammation.

Authors:  Junxi Wu; Jun Li; Nannan Zhang; Cuihua Zhang
Journal:  Basic Res Cardiol       Date:  2011-03-23       Impact factor: 17.165

2.  Umbilical cord-derived mesenchymal stem cells for treating osteoarthritis of the knee: a single-arm, open-label study.

Authors:  Ismail Hadisoebroto Dilogo; Anissa Feby Canintika; Alberto Lastiko Hanitya; Jeanne Adiwinata Pawitan; Isabella Kurnia Liem; Jacub Pandelaki
Journal:  Eur J Orthop Surg Traumatol       Date:  2020-01-27

Review 3.  Umbilical cord-derived mesenchymal stem cells: Their advantages and potential clinical utility.

Authors:  Tokiko Nagamura-Inoue; Haiping He
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

4.  Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial.

Authors:  Serge Masson; Pietro Caironi; Caterina Fanizza; Ralf Thomae; Roberto Bernasconi; Andrea Noto; Roberto Oggioni; Giovanni Stefano Pasetti; Marilena Romero; Gianni Tognoni; Roberto Latini; Luciano Gattinoni
Journal:  Intensive Care Med       Date:  2014-10-16       Impact factor: 17.440

Review 5.  Immunological applications of stem cells in type 1 diabetes.

Authors:  Paolo Fiorina; Julio Voltarelli; Nicholas Zavazava
Journal:  Endocr Rev       Date:  2011-08-23       Impact factor: 19.871

6.  Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study.

Authors:  Ranhua Jiang; Zhibo Han; Guangsheng Zhuo; Xiaodan Qu; Xue Li; Xin Wang; Yuankang Shao; Shimin Yang; Zhong Chao Han
Journal:  Front Med       Date:  2011-03-17       Impact factor: 4.592

7.  Transplantation of placenta-derived mesenchymal stem cells in the EAE mouse model of MS.

Authors:  Yonit Fisher-Shoval; Yael Barhum; Ofer Sadan; Shlomit Yust-Katz; Tali Ben-Zur; Nirit Lev; Chen Benkler; Moshe Hod; Eldad Melamed; Daniel Offen
Journal:  J Mol Neurosci       Date:  2012-05-26       Impact factor: 3.444

Review 8.  Implantation of human umbilical cord mesenchymal stem cells for ischemic stroke: perspectives and challenges.

Authors:  Yingchen Li; Guoheng Hu; Qilai Cheng
Journal:  Front Med       Date:  2014-12-09       Impact factor: 4.592

9.  Immunosuppressive properties of Wharton's jelly-derived mesenchymal stromal cells in vitro.

Authors:  Haiping He; Tokiko Nagamura-Inoue; Atsuko Takahashi; Yuka Mori; Yuki Yamamoto; Takahisa Shimazu; Hajime Tsunoda; Arinobu Tojo
Journal:  Int J Hematol       Date:  2015-07-31       Impact factor: 2.490

Review 10.  Stem Cell-Based Therapy for Asherman Syndrome: Promises and Challenges.

Authors:  Yiyin Gao; Guijie Wu; Ying Xu; Donghai Zhao; Lianwen Zheng
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.